Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and absolute bioavailability study of [14C]PF-06882961 in healthy adult men
NL-OMON49480Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danuglipron in type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Primary endpoint: Total recovery of radioactivity in urine and feces. Started Jul 2020; status: active, not recruiting.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON49480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49480.